Glycaemic control and hypoglycaemia in the PRESENT study

Almustafa, M.; Yeo, Jing Ping; Khutsoane, Duma

doi:10.1016/j.diabres.2008.06.007

Cited by 5 publications

(1 citation statement)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[84–88] In one subanalysis of this trial, subjects were enrolled into different subgroups depending on age, BMI or ethnic background. [89] From data collected this way, it was seen that age and BMI did not affect the HbA 1c -lowering qualities or the safety of BIAsp 30. Ethnic origin, on the other hand, did seem to play a role in HbA 1c levels, being highest for Black individuals at baseline (11.6%) compared with Asian/Pacific Island (9.3%), Middle Eastern/Arabic (9.6%) and White (9.6%) populations.…”

Section: Clinical Evidence Translating To Clinical Practicementioning

confidence: 99%

Ten Years of Experience with Biphasic Insulin Aspart 30

Liebl

Prusty

Valensi

et al. 2012

Drugs

View full text Add to dashboard Cite

Biphasic insulin aspart 30 (BIAsp 30) includes 30% soluble rapid-acting insulin aspart (IAsp) along with an intermediate-acting 70% protaminated IAsp that provides coverage of prandial and basal insulin in a single injection. As BIAsp 30 has been available internationally for 10 years, this review provides a comprehensive overview of the discovery of BIAsp 30, its pharmacokinetic and pharmacodynamic profile, safety and efficacy outcomes from the clinical trial programme, ‘real-life’ clinical insights provided by observational study data, and cost effectiveness and quality-of-life information. These studies have demonstrated that BIAsp 30 once or twice daily is an appropriate option for insulin initiation. BIAsp 30 also provides a switch option in patients on biphasic human insulin (BHI). Switching from BHI to BIAsp 30 is associated with improved postprandial glucose (PPG) and reduced nocturnal and major hypoglycaemia, although daytime hypoglycaemia is higher with BIAsp 30. Intensification of BIAsp 30 can be achieved by increasing the number of daily doses up to three times daily with meals. Therefore, BIAsp 30 provides an intensification option for individuals who are not achieving control with basal insulin and would prefer the simplicity of a single biphasic insulin instead of progressing to a basal-bolus approach. BIAsp 30 has a simple dose-titration algorithm, which enables patients to effectively self-titrate their insulin dose. Cost-effectiveness analyses have demonstrated that BIAsp 30 is cost effective or dominant compared with BHI 30 or insulin glargine in a number of healthcare settings. In conclusion, BIAsp 30 offers a simple and flexible option for insulin initiation and intensification that provides coverage of both fasting and prandial glucose.

show abstract

Section: Clinical Evidence Translating To Clinical Practicementioning

confidence: 99%

Ten Years of Experience with Biphasic Insulin Aspart 30

Liebl

Prusty

Valensi

et al. 2012

Drugs

View full text Add to dashboard Cite

show abstract

Initiation with once-daily BIAsp 30 results in superior outcome compared to insulin glargine in Asians with type 2 diabetes inadequately controlled by oral anti-diabetic drugs

Kalra

Plata-Que

Kumar

et al. 2010

Diabetes Research and Clinical Practice

View full text Add to dashboard Cite

Efficacy and safety of biphasic insulin aspart 70/30 in type 2 diabetes patients of different race or ethnicity (INITIATEplus trial)

Trippe¹,

Shepherd

Coulter³

et al. 2012

Current Medical Research and Opinion

View full text Add to dashboard Cite

Diabetes self-management with BIAsp 30 using an easily followed self-titration algorithm produced low hypoglycemia rates. All subgroups achieved A1C reductions >2.1% and FPG declines >82 mg/dL that were similar across groups, demonstrating that self-titration of BIAsp 30 can successfully be pursued in a primary care setting by patients who had previously failed to meet ADA A1C targets under oral antidiabetes therapy, with race or ethnicity not an obstacle to achieving better glycemic control.

show abstract

Glycaemic control and hypoglycaemia in the PRESENT study

Cited by 5 publications

References 22 publications

Ten Years of Experience with Biphasic Insulin Aspart 30

Ten Years of Experience with Biphasic Insulin Aspart 30

Initiation with once-daily BIAsp 30 results in superior outcome compared to insulin glargine in Asians with type 2 diabetes inadequately controlled by oral anti-diabetic drugs

Efficacy and safety of biphasic insulin aspart 70/30 in type 2 diabetes patients of different race or ethnicity (INITIATEplus trial)

Contact Info

Product

Resources

About